Compare MSD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | NYXH |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 126.0M |
| IPO Year | N/A | 2021 |
| Metric | MSD | NYXH |
|---|---|---|
| Price | $7.24 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 98.8K | ★ 241.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $1.31 |
| 52 Week High | $7.94 | $8.59 |
| Indicator | MSD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 18.84 |
| Support Level | $6.91 | N/A |
| Resistance Level | $7.48 | $5.02 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 25.79 | 5.03 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.